SNSamuel S. Nunn

Samuel S. Nunn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samuel S. Nunn has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Agnieszka Sulima

    Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892, USA

    1 shared publication
  • Anthony L. Riley

    Psychopharmacology Laboratory, Department of Neuroscience, Center for Neuroscience and Behavior, American University, Washington, D.C., 20016, USA

    1 shared publication
  • Hayley N. Manke

    Psychopharmacology Laboratory, Center for Neuroscience and Behavior, Department of Neuroscience, American University, 4400 Massachusetts Ave, NW, Washington, DC 20016, USA

    1 shared publication
  • Kenner C. Rice

    Department of Health and Human Services,Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Re-search Program, NIDA and the NIAAA, NIH,Bethesda,USA, USA

    1 shared publication

Latest Publications

  • Open Access

    Effects of Serial Polydrug Use on the Rewarding and Aversive Effects of the Novel Synthetic Cathinone Eutylone

    by Hayley N. Manke, Samuel S. Nunn, Agnieszka Sulima, Kenner C. Rice, Anthony L. Riley

    Background: As individual synthetic cathinones become scheduled and regulated by the Drug Enforcement Administration (DEA), new ones regularly are produced and distributed. One such compound is eutylone, a novel third-generation synthetic cathinone whose affective properties (and abuse potential) are largely unknown. The following experiments begin to characterize these effects and how they may be impacted by drug history (a factor affecting reward/aversion for other drugs of abuse). Methods: Eutylone was assessed for its ability to induce conditioned taste avoidance (CTA; aversive effect) and conditioned place preference (CPP; rewarding effect) and their relationship (Experiment 1). Following this, the effects of exposure to cocaine or 3,4-methylenedioxymethamphetamine [MDMA] on eutylone’s affective properties were investigated (Experiment 2). Results: Eutylone produced dose-dependent CTA and CPP (Experiment 1), and these endpoints were unrelated. Pre-exposure to cocaine and MDMA differentially impacted taste avoidance induced by eutylone (MDMA > cocaine) and did not impact eutylone-induced place preference. Conclusions: These data indicate that eutylone, like other synthetic cathinones, has co-occurring, independent rewarding and aversive effects that may contribute to its abuse potential and that these effects are differentially impacted by drug history. Although these studies begin the characterization of eutylone, future studies should examine the impact of other factors on eutylone’s affective properties and its eventual reinforcing effects (i.e., intravenous self-administration [IVSA]) to predict its use and abuse liability.